

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1069)

**(1) RESULTS OF THE RIGHTS ISSUE ON THE
BASIS OF TWO (2) RIGHTS SHARES FOR EVERY ONE (1)
EXISTING SHARE HELD ON THE RECORD DATE
ON A NON-UNDERWRITTEN BASIS; AND
(2) PLACING OF THE PLACING SHARES**

References are made to (i) the announcements of China Health Technology Group Holding Company Limited (the “**Company**”) dated 27 March 2026, 16 June 2026 and 19 August 2026 (the “**Announcements**”); (ii) the circular of the Company dated 24 April 2026; (iii) the poll results announcement of the Company dated 12 May 2026; and (iv) the prospectus of the Company dated 26 May 2026 (the “**Prospectus**”) in relation to, among other things, the Rights Issue and the Placing. Capitalised terms used herein shall have the same meanings as those defined in the Prospectus unless the context otherwise requires.

RESULTS OF THE PLACING AND THE RIGHTS ISSUE

As disclosed in the Announcements, a total of 3 valid applications and acceptances under the PALs had been received for a total of 58,919,695 Rights Shares, representing approximately 28.62% of the total number of 205,848,440 Rights Shares available for subscription under the Rights Issue.

Based on the results of the Rights Issue and in accordance with the terms of the Placing Agreement, the Placing Agent has conducted the Placing on a best effort basis to procure Placees to subscribe for up to 146,928,745 Placing Shares during the Placing Period from Wednesday, 17 June 2026 up to 4:00 p.m. on Monday, 6 July 2026.

The Board hereby announces that all the conditions precedent to the Placing were fulfilled. Accordingly, the Placing became unconditional at 4:00 p.m. on Tuesday, 7 July 2026. A total of 146,928,745 Placing Shares, representing approximately 71.38% of the total number of 205,848,440 Rights Shares available for subscription under the Rights Issue, were successfully placed to not less than six Placees at the Placing Price of HK\$0.25 per Placing Share pursuant to the terms of the Placing Agreement and the completion of the Placing took place on Wednesday, 26 August 2026. The gross proceeds raised under the Placing on a standalone basis amounted to approximately HK\$36,732,186.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, all the Placees and their respective ultimate beneficial owners (if applicable) are third parties independent of, and not connected with or acting in concert with, the Company, its connected persons (as defined under the Listing Rules) and their respective associates (as defined under the Listing Rules).

Based on the results of acceptance of the Rights Issue and the results of the Placing, the total number of Rights Shares taken by the Shareholders and the Placing Shares taken by the Placees amounted to a total of 205,848,440 Shares, representing 100% of the total number of 205,848,440 Rights Shares available for subscription under the Rights Issue. As a result, the Rights Issue was fully subscribed.

INTENDED USE OF THE NET PROCEEDS FROM THE RIGHTS ISSUE AND THE PLACING

The gross proceeds raised from the Rights Issue and the Placing were approximately HK\$51.5 million and the net proceeds from the Rights Issue and the Placing (after deducting all necessary costs and expenses) were approximately HK\$50.0 million. The Company intends to apply the net proceeds in the following manner: (a) approximately HK\$22.0 million for the expansion of the scale of ginseng plantation by various means, including but not limited to acquisition of forests and other plantation sites and related marketing and promotion activities to support the Group's expansion in the ginseng business; (b) approximately HK\$18.0 million for investment in the medical aesthetics industry, including but not limited to the acquisition of equipment, establishment of operational facilities and related business development; and (c) approximately HK\$10.0 million for general working capital of the Group, including salary expenses and other office and corporate expenses.

EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the shareholding structure of the Company immediately before and after the completion of the Rights Issue and the Placing is set out below:

Shareholders	Immediately before completion of the Rights Issue and the Placing		Immediately after completion of the Rights Issue but before the Placing		Immediately after completion of the Rights Issue and the Placing	
	Number of Shares	Approximate (%)	Number of Shares	Approximate (%)	Number of Shares	Approximate (%)
Ms. Huang Hou (“ Ms. Huang ”) (Note 1)	8,056,800	7.83	8,056,800	4.98	8,056,800	2.61
Public Shareholders						
Placees	–	–	–	–	146,928,745	47.58
Other Public Shareholders	94,867,420	92.17	153,787,115	95.02	153,787,115	49.81
Total	<u>102,924,220</u>	<u>100.00%</u>	<u>161,843,915</u>	<u>100.00%</u>	<u>308,772,660</u>	<u>100.00%</u>

Notes:

- These 8,056,800 Shares comprise 1,020,000 Shares and 7,036,800 Shares held by Ms. Huang through China Sports Asset Management Co., Limited (“**China Sports**”) and Zhonggangtong International Holding Group Co., Limited (“**Zhonggangtong International**”), respectively, each of which is ultimately controlled by Ms. Huang. Pursuant to Divisions 7 and 8 of Part XV of the Securities and Futures Ordinance, Ms. Huang is deemed to have an interest in all Shares in which each of China Sports and Zhonggangtong International has, or is deemed to have, an interest.
- Certain percentage figures included in the table above have been subject to rounding adjustments. Accordingly, figures shown as total may not be an arithmetic aggregation of the figures preceding them.

By Order of the Board of
China Health Technology Group Holding Company Limited
Bi Xue
Chairman and Executive Director

Hong Kong, 26 August 2026

As at the date of this announcement, the Board comprises Ms. Bi Xue, Mr. Leung Ka Wai and Ms. Wong Hoi Ying as the executive Directors; and Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie as the independent non-executive Directors.